267 related articles for article (PubMed ID: 15176047)
1. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway.
Lee SO; Lou W; Johnson CS; Trump DL; Gao AC
Prostate; 2004 Aug; 60(3):178-86. PubMed ID: 15176047
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells.
Pu YS; Hour TC; Chuang SE; Cheng AL; Lai MK; Kuo ML
Prostate; 2004 Jul; 60(2):120-9. PubMed ID: 15162378
[TBL] [Abstract][Full Text] [Related]
3. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
4. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
[TBL] [Abstract][Full Text] [Related]
5. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
6. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.
DeMiguel F; Lee SO; Lou W; Xiao X; Pflug BR; Nelson JB; Gao AC
Prostate; 2002 Jul; 52(2):123-9. PubMed ID: 12111703
[TBL] [Abstract][Full Text] [Related]
7. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells.
Lee SO; Lou W; Qureshi KM; Mehraein-Ghomi F; Trump DL; Gao AC
Prostate; 2004 Sep; 60(4):303-9. PubMed ID: 15264241
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
[TBL] [Abstract][Full Text] [Related]
11. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
Xie S; Lin HK; Ni J; Yang L; Wang L; di Sant'Agnese PA; Chang C
Prostate; 2004 Jun; 60(1):61-7. PubMed ID: 15129430
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.
Mora LB; Buettner R; Seigne J; Diaz J; Ahmad N; Garcia R; Bowman T; Falcone R; Fairclough R; Cantor A; Muro-Cacho C; Livingston S; Karras J; Pow-Sang J; Jove R
Cancer Res; 2002 Nov; 62(22):6659-66. PubMed ID: 12438264
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
14. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
[TBL] [Abstract][Full Text] [Related]
16. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
17. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
18. Androgens block interleukin-1 beta-induced promatrilysin expression in prostate carcinoma cells.
Stratton MS; Greenstein B; Udayakumar TS; Nagle RB; Bowden GT
Prostate; 2002 Sep; 53(1):1-8. PubMed ID: 12210475
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms by which interleukin-6 regulates prostate-specific antigen gene expression in prostate LNCaP carcinoma cells.
Tsui KH; Lin YF; Chen YH; Chang PL; Juang HH
J Androl; 2011; 32(4):383-93. PubMed ID: 21051589
[TBL] [Abstract][Full Text] [Related]
20. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]